Medios Stock

Medios ROE

The Return on Equity (ROE) of Medios (ILM1.DE) as of Aug 14, 2026 is 2.99 %. In the previous year, Return on Equity (ROE) was 2.46 % — a change of 21.49% (higher).

ROE

2.99 %

YoY

21.49%

Last updated:

In 2026, Medios's return on equity (ROE) was 2.99 %, a 21.49% increase from the 2.46 % ROE in the previous year.

Access this data via the Eulerpool API

Medios Stock analysis

What does Medios do? Medios AG is a leading company in the supply of high-quality specialty preparations to patients. The company was founded in Berlin in 2004 and has been listed on the Frankfurt Stock Exchange since 2018. Medios AG quickly achieved a strong position in the German healthcare market and currently employs approximately 300 employees at multiple locations in Germany. The business model of Medios AG is based on the production and distribution of high-quality specialty preparations. These are developed and produced in close collaboration with customers such as hospitals and outpatient clinics. Medios AG's products are typically used to treat rare and chronic diseases, such as immunological diseases, cancer, and metabolic disorders. Medios AG offers a wide range of products and services. The company is divided into three areas. The first area is Medios AG's core business, the distribution of specialty preparations. This area includes the development, production, and distribution of specialty preparations. The portfolio includes, for example, medications for pain and inflammation, as well as preparations for the treatment of Parkinson's and Alzheimer's diseases. Another important aspect in the field of specialty preparations is the supply of patients with parenteral nutrition solutions. These are used in both outpatient and inpatient settings to provide care for patients with severe diseases. The second area is supply services. Here, Medios offers a comprehensive range of services to support customers in hospital care and outpatient patient care. An important aspect of this area is the support of hospitals in dealing with delegations. For example, training is offered to educate hospital staff on the management of certain diseases. The third area is clinical study support. Medios AG offers services and products to support customers in clinical studies. The range includes criteria for patient-related logistics, the delivery of placebos and blinded medications, as well as specialty preparations and parenteral nutrition solutions. In each of these areas, Medios brings its high expertise and experience to develop the best possible solutions for customers and patients. Overall, Medios AG has established itself as an important partner for the German healthcare sector. The company pursues a clear strategy focused on the development and production of specialty preparations for the treatment of serious and rare diseases. The company places the highest value on the quality and safety of its products, as well as comprehensive consultation and customer care. Medios has a strong network of partners and suppliers in the healthcare industry and is a respected contact for customers and other market participants due to its experience and expertise. Medios is one of the most popular companies on Eulerpool.

ROE Details

Decoding Medios's Return on Equity (ROE)

Medios's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Medios's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Medios's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Medios’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Medios stock

Return on Equity (ROE) of Medios is 2.99 % in 2026.

Return on Equity (ROE) of Medios changed from 2.46 % to 2.99 %, representing a 21.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Medios since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Medios with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Medios

All Key Metrics — Medios